摘要
目的:探讨临床应用伊立替康致药品不良反应(ADR)发生的特点及规律,为临床合理用药提供参考。方法:采用回顾性研究方法,收集2011年6月-2015年1月我院应用伊立替康的56例晚期恶性肿瘤患者出现ADR的相关信息,按照性别、年龄、病种、美国东部肿瘤协作组(ECOG)评分、用药情况、ADR累及器官/系统、临床表现以及转归情况等进行描述性统计分析。结果:56例患者发生ADR累及器官/系统以骨髓造血系统所占比例最高(100%),其次为消化系统;其中Ⅰ~Ⅱ级ADR占87.20%,Ⅲ~Ⅳ级ADR占12.80%。64.50%的ADR在用药1周内发生。ADR转归情况方面,85.71%(48/56)的患者给予支持治疗后恢复,继续后续周期化疗,其余8例给予药物减量并对症治疗后好转。结论:伊立替康采用规范化疗方案给药剂量,其临床耐受性良好,ADR多数表现轻微且对症处理均可恢复。应加强对患者随访,防止严重ADR的发生。
OBJECTIVE:To explore the characteristics and regularities of the adverse drug reactions(ADRs)induced by irinotecan,in order to provide reference for clinical application. METHODS:In retrospective study,56 cases of irinotecan-induced ADR collected from our hospital during Jun. 2011-Jan.2015 were analyzed statistically in respects of gender,age,disease types,ECOG score,medication,organs/systems involved in ADR,clinical manifestations,outcome,etc. RESULTS:All 56 patients suffered from ADR,among which the percentage of hematopoietic system accounted for the highest(100%),and followed by digestive system;the grade Ⅰ-Ⅱ ADRs accounted for 87.20%,the grade Ⅲ-Ⅳ ADRs accounted for 12.80%. 64.50% of ADRs occurred within 1 week. In respect of conversion,85.71%(48/56)of the patients recovered with supportive care and continued chemotherapy,the remaining 8 cases had to reduce the dose of chemotherapy and then recovered. CONCLUSIONS:With regular dose,irinotecan is well tolerated. Since ADRs induced by irinotecan are slight,all the ADRs are well managed. It is important to enhance follow-up observations of patients to prevent some serious ADRs.
出处
《中国药房》
CAS
北大核心
2016年第5期635-637,共3页
China Pharmacy
关键词
伊立替康
药品不良反应
合理用药
分析
Irinotecan
Adverse drug reactions
Rational drug use
Analysis